Advertisement
Advanced searchCitation search
Skip main navigation
Close Drawer MenuOpen Drawer Menu
No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 Jun 2004

PRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT

    View All Author Information
    https://doi.org/10.1097/01.ju.0000113728.46439.02

    Abstract

    Purpose:

    The minimal efficacy of standard therapy for metastatic renal cell carcinoma (RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown promise in phase II trials and yet none have improved survival over standard therapy in phase III trials. We examined existing data relevant to standard therapy and clinical trial methodology in RCC to understand patient, disease and trial design factors that have impacted clinical trial outcome and drug evaluation. Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC.

    Materials and Methods:

    A comprehensive review of published retrospective analyses and phase II/phase III trials in patients with metastatic RCC was undertaken. Publications with patient selection and/or therapeutic implications in our judgment are presented and evaluated.

    Results:

    Patients with good performance status and access to centers with experienced staff may appropriately receive high dose interleukin-2 after consideration of the relative risks and benefits. Alternatively low dose, single agent cytokine regimens are acceptable. Novel agents may be tested in untreated and refractory RCC. Consideration of the prognostic factors of a given phase II cohort is essential when interpreting single arm clinical trial results. RCC histological subtypes continue to be distinguished biologically and treatment relevant to the vascular endothelial growth factor pathway is most appropriately targeted to clear cell RCC. Nephrectomy in metastatic RCC may impact evaluation of the tumor response and survival in metastatic RCC. Thus, consideration of nephrectomy status in phase II trials and stratification in phase III trials is warranted. Clinical trials that include patients with central nervous system metastases should have standardized treatment of these metastases prior to systemic therapy. Objective response rate as an end point should be used with caution, given its unreliable history in metastatic RCC. Novel trial designs using time to disease progression may allow for interpretation of the antitumor effect in the absence of tumor shrinkage.

    Conclusions:

    Metastatic renal carcinoma is a model disease for the design of clinical trials and testing of novel agents. Novel trial designs and end points should be considered to evaluate new agents in RCC. Phase III trials must be carefully performed with the most promising agents to impact survival in this disease.

    References

    • 1 Atkins M.B.: A randomized phase III trial of high-dose IL-2 versus subcutaneous IL-2 in patients with metastatic renal cell carcinoma. Presented at Chiron Investigator's Meeting, Phoenix, Arizona, March 6, 2003 Google Scholar
    • 2 : Randomized study of high-dose and low-dose interleukin-2 in patients with meta-static renal cancer. J Clin Oncol2003; 21: 3127. Google Scholar
    • 3 Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet1999; 353: 14. Google Scholar
    • 4 : Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol1999; 17: 2859. Google Scholar
    • 5 : Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma Groupe Francais d'Immunotherapie. N Engl J Med1998; 338: 1272. Google Scholar
    • 6 : Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002; 20: 289. Google Scholar
    • 7 : Prognostic factors (PF) for survival in previously untreated metastatic renal cell cancer (RCC): a comprehensive evaluation and validation of established risk groups. Progr Proc Am Soc Clin Oncol2003; 22: 385. abstract 1545. Google Scholar
    • 8 : Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol2002; 13: 1460. Google Scholar
    • 9 : Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol2002; 20: 4559. Google Scholar
    • 10 : The Heidelberg classification of renal cell tumours. J Pathol1997; 183: 131. Google Scholar
    • 11 : Classification of renal cell carcinoma: Workgroup No. 1 Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer1997; 80: 987. Google Scholar
    • 12 : Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol1995; 22: 3. Google Scholar
    • 13 : VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. Oncogene2001; 20: 5393. Google Scholar
    • 14 : Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. J Mol Med1999; 77: 505. Google Scholar
    • 15 : Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA1996; 93: 10595. Google Scholar
    • 16 : Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet1997; 16: 68. Google Scholar
    • 17 : Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol2002; 168: 51. Link, Google Scholar
    • 18 : Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol2002; 167: 65. Link, Google Scholar
    • 19 : Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol1999; 17: 523. Google Scholar
    • 20 : Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res1995; 55: 658. Google Scholar
    • 21 : Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol1997; 181: 136. Google Scholar
    • 22 : Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001; 345: 1655. Google Scholar
    • 23 : European Organization for the Research and Treatment of Cancer (EORTC) Genitourinary Group: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001; 358: 966. Google Scholar
    • 24 : Effect of response criteria on outcome assessment for patients with advanced renal carcinoma. Progr Proc Am Soc Clin Oncol2003; 22: 385. abstract 1546. Google Scholar
    • 25 : Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol1984; 2: 169. Google Scholar
    • 26 : Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer1998; 83: 2548. Google Scholar
    • 27 : Gamma-knife radiosurgery for brain metastases of renal cell carcinoma: results in 23 patients. Acta Neurochir1998; 140: 549. Google Scholar
    • 28 : The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys2000; 47: 1007. Google Scholar
    • 29 : Gamma knife radiosurgery for renal cell carcinoma brain metastases. J Neurosurg2002; 97: 489. Google Scholar
    • 30 : Reporting results of cancer treatment. Cancer1981; 47: 207. Google Scholar
    • 31 : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000; 92: 205. Google Scholar
    • 32 : Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am1993; 20: 303. Google Scholar
    • 33 : Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol1997; 158: 740. Link, Google Scholar
    • 34 : Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol1999; 17: 2521. Google Scholar
    • 35 : Interferon alfa-2a and 13-cisretinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol1995; 13: 1950. Google Scholar
    • 36 : Phase III trial of interferon alfa-2a with or without 13-cisretinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol2000; 18: 2972. Google Scholar
    • 37 : EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer1995; 71: 371. Google Scholar
    • 38 : Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol1992; 3: 301. Google Scholar
    • 39 : Phase III randomized trial of interleukin-2 with or without lymphokine- activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer1995; 76: 824. Google Scholar
    • 40 : A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med2003; 349: 427. Google Scholar
    • 41 : Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol1993; 46: 959. Google Scholar
    • 42 : Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol2002; 20: 4478. Google Scholar
    • 43 : Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol2003; 22: 630. abstract 2532. Google Scholar

    From the Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California

    © 2004 by American Urological Association, Inc.
    Copyright © 2022 American Urological Association Education and Research, Inc.

    COPYRIGHT AND PERMISSIONS: The Journal of Urology® is the Official Journal of the American Urological Association Education and Research, Inc. and is published monthly by Wolters Kluwer Health Inc. The American Urological Association grants the Publisher full and exclusive publishing and distribution rights, worldwide, for both print and electronic media. Therefore no portions of the work(s) can be reproduced without written consent from the Publisher. Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the Get Content & Permissions link under the Article Tools box that appears on the right side of the page. For questions about the Rightslink service, e-mail [email protected] or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on authors permission requests are available at Journal Permission.

    For translation rights requests, contact Translations. For license to republish and distribute requests, contact Licensing. For special projects and reprints (U.S./Canada), contact Alan Moore or [email protected]. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at [email protected] or [email protected].

    PRIVACY POLICY: Access AUA’s Privacy Policy (Privacy Policy).

    Advertisement